CYTOF.US Altamira Therapeutics Ltd.
- Market cap
- USD 406K
- P/E
- -
- P/B
- 0.10x
- ROE
- -128.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is CYTOF.US undervalued?
Graham numberThe Graham number of Altamira Therapeutics Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Altamira Therapeutics Ltd. fundamental analysis
No fundamental analysis for Altamira Therapeutics Ltd. yet.
Altamira Therapeutics Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the tre…
Full company profileAltamira Therapeutics Ltd. financial statements
Altamira Therapeutics Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -2.38M | -1.23M | -80.6K | - |
| Operating Income | -5.28M | -7.52M | -18.9M | -6.60M | -6.92M |
| EBITDA | - | -7.35M | -18.5M | -6.81M | -8.31M |
| Net Income | -8.20M | -18.7M | -27.8M | -4.31M | -8.46M |
| EPS | -287 | -499 | -471 | -2.91 | -1.81 |
| Balance Sheet | |||||
| Total Assets | 20.8M | 21.0M | 6.81M | 9.14M | 8.65M |
| Total Liabilities | 4.03M | 6.71M | 15.8M | 1.47M | 2.09M |
| Shareholders' Equity | 16.8M | 14.3M | -8.99M | 7.68M | 6.57M |
| Cash & Short-term Investments | 11.3M | 1.08M | 16.6K | 734K | 999K |
| Cash Flow | |||||
| Operating Cash Flow | -4.84M | -15.0M | -9.09M | -11.5M | -6.11M |
| Capital Expenditure | 2.32M | 3.64M | 2.24M | 0.00 | 103K |
| Free Cash Flow | -7.16M | -18.6M | -11.3M | -11.5M | -6.22M |
| Ratios | |||||
| ROE | -48.9% | -130.9% | - | -56.1% | -128.8% |
| ROA | -39.4% | -89.0% | -407.7% | -47.1% | -97.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Altamira Therapeutics Ltd. dividends
Altamira Therapeutics Ltd. has not paid dividends in the last 7 fiscal years.
Last stock split: 1:20 on Dec 13, 2023.
Who owns Altamira Therapeutics Ltd.
- Insiders 18.80%
- Institutions 4.00%
- Public & others 77.20%
- Shares outstanding 5.72M
- Free float 4.12M
Altamira Therapeutics Ltd. company profile
- Company name
- Altamira Therapeutics Ltd.
- Ticker
- CYTOF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- Clarendon House, Hamilton, Bermuda, HM 11
- Phone
- 441 295 5950
- Website
- altamiratherapeutics.com
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Altamira Therapeutics Ltd. management
4- Dr. Thomas Meyer Ph.D.Founder, President, Chairman, CEO & MD · born 1968
- Mr. Marcel Gremaud CPAChief Financial Officer · born 1958
- Dr. Covadonga PanedaChief Operating Officer · born 1974
- Dr. Samuel A. Wickline M.D.Chief Scientific Adviser · born 1953